The biotech and biopharma industry has struggled in recent years with a lack of investment. While GlobalData has tracked an uptick in investment into companies, this is mostly in earlier-stage biotech and biopharma, meaning those who were already struggling continue to battle with low funds.
At the same time, government-led funding schemes are being reduced or scrapped, further impeding these companies’ access to finance to run research.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData is the parent company of the Clinical Trials Arena.
In this podcast episode, the Clinical Trials Arena spoke to Ali Pashazadeh, CEO of Treehill Partners and Michelle Hoffmann, executive director of the Chicago Biomedical Consortium, who explain the potential impact these funding cuts could have on biotech and biopharma companies ability to run clinical trials.
You can listen to the podcast here:
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
